|
|
Parent Company
Eisai Inc. is supported by a strong parent company, Eisai Co., Ltd., which was founded in Japan in 1941 as Nihon Eisai Co., Ltd. To this day, Eisai Co., Ltd. is one of the few Japanese pharmaceutical companies to undertake aggressive global expansion through substantial infrastructure investments in its foreign affiliates. These affiliates conduct research and development, manufacturing, and sales and marketing in the United States, Europe and Asia.
Globally, most of Eisai Co., Ltd.'s sales are derived from treatments for central nervous system diseases and gastrointestinal disorders. Eisai has more than 9,000 employees worldwide and is a publicly traded company whose stock trades on the Tokyo Stock Exchange and Osaka Securities Exchange and is listed in the United States under an American Depositary Receipt with the ticker symbol of ESALY.
Backed by the strong heritage and resources of Eisai Co., Ltd., Eisai Inc. has built an integrated U.S. pharmaceutical business. From a financial perspective, Eisai Inc. has become increasingly important to Eisai Co., Ltd. and its worldwide presence. Eisai Inc. achieved sales of approximately $2.2 billion in fiscal year 2005 (year ending March 31, 2006). The company's growth has been impressive - between 1998 and 2005, Eisai Inc. moved up rapidly in the rankings (based on retail sales) of US pharmaceutical companies from No. 44 to No. 19.
 Printer Friendly Version
|
|
